- A meta-analysis shows that adjuvant transarterial chemoembolization (TACE) is associated with a survival benefit in hepatocellular carcinoma (HCC) with microvascular invasion (MVI).
Why this matters
- There is no currently recommended postoperative treatment for HCC with MVI.
- The study is the first systematic review and meta-analysis to compare resection with and without adjuvant TACE in HCC with MVI.
- Systematic review and meta-analysis of 12 studies (n=2190).
- Funding: Various nonindustry sources.
- In a meta-analysis of 10 studies, TACE was associated with better OS than resection alone at 1 year (OR, 0.33; P<.001 years p and>
- In a meta-analysis of 11 studies, TACE was associated with better DFS at 1 year (OR, 0.45; P<.001 years p and>
- A subgroup analysis of 4 studies that included tumors >5 cm showed better survival with TACE at:
- 1 year (OS: OR, 0.29 [P<.001 or>
- 3 years (OS: OR, 0.45 [P<.001 or>
- 5 years (OS: OR, 0.38 [P=.001]; DFS: OR, 0.42 [P=.013]).
- Only 1 study was a randomized controlled trial.
- All studies were conducted in China.